.jpeg)
When was Nilotinib launched?
Nilotinib (Nilotinib, which was approved for medical use by the U.S. Food and Drug Administration (FDA) in October 2007 and the European Medicines Agency (EMA) in September 2009, followed by other countries, has been shown to improve the condition of patients with chronic myelogenous leukemia (CML) by reducing the number of cancer cells with the Philadelphia chromosome and normalizing white blood cell levels. Nilotinib is a second-generation tyrosine kinase inhibitor (TKI), formerly known as AMN107. In May 2014, nilotinib was approved by the National Medical Products Administration for marketing in China, and subsequently entered the scope of Class B medical insurance through relevant policies.
[ 免责声明 ] 本页面内容来自公开渠道（如FDA官网、Drugs官网、原研药厂官网等），仅供持有医疗专业资质的人员用于医学药学研究参考，不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市，不适用于中国境内销售和使用。如需治疗，请咨询正规医疗机构。本站不提供药品销售或代购服务。
